Bussulfano e melfalano como regime de condicionamento para o transplante autogênico de células-tronco hematopoéticas na leucemia mielóide aguda em primeira remissão completa

Bueno, Nadjanara Dorna; Dulley, Frederico Luiz; Saboya, Rosaura; Filho, José Ulysses Amigo; Piron-Ruiz, Lílian; Sturaro, Daniel; Chamone, Dalton A. F.

doi:10.1590/s1516-84842008000500005

Cited by 1 publication

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conditioning with the BU/Mel combination ( 15 - 17 ) is most used in our service as these agents are active in the treatment of AML but cause less hematuria. The conclusion in this study is that Allo-HSCT in AML patients in 1st CR showed similar results to the literature.…”

Section: Discussionmentioning

confidence: 99%

“…Acute and chronic GvHD were important in the survival of patients thus supporting published data. ( 14 , 28 , 29 ) The BU/Mel conditioning regimen ( 15 - 17 ) proved to be a valid alternative to BU/Cy ( 12 , 13 ) as it decreases the incidence of hemorrhagic cystitis and provides a good survival rate.…”

Section: Discussionmentioning

confidence: 99%

“…(14) The association of busulfan and melphalan (BU/Mel) (15-17) is the most used regimen in this service in order to decrease the incidence of hematuria associated with Cy as these agents are active in the treatment of AML.…”

Section: Introductionmentioning

confidence: 99%

“…The use of a cyclophosphamide (Cy) and busulfan (BU) ( 12 , 13 ) combination is the most used conditioning for Allo-HSCT, followed by total body irradiation combined with Cy. ( 14 ) The association of busulfan and melphalan (BU/Mel) ( 15 - 17 ) is the most used regimen in this service in order to decrease the incidence of hematuria associated with Cy as these agents are active in the treatment of AML.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission

Bueno

Dulley

Saboya

et al. 2011

Rev. Bras. Hematol. Hemoter.

Self Cite

View full text Add to dashboard Cite

BackgroundAllogeneic hematopoietic stem cell transplantation with HLA-identical donors has been established for the treatment of acute myeloid leukemia patients for over 30 years with a cure rate of 50% to 60%.ObjectivesTo analyze the overall survival of patients and identify factors that influence the outcomes of this type of transplant in patients in 1st complete remission who received a busulfan and melphalan combination as conditioning regimen.MethodsTwenty-five consecutive patients with acute myeloid leukemia were enrolled between 2003 and 2008. The median age was 34 years old (Range: 16 - 57 years). All patients received cyclosporine and methotrexate for prophylaxis against graft-versus-host disease. Median neutrophil engraftment time was 16 days (Range: 7 - 22 days) and 17 days (Range: 7 - 46 days) for platelets. Sinusoidal obstructive syndrome was observed in three patients, seven had grade II acute graft-versus-host disease and one extensive chronic graft-versus-host disease.ResultsThe overall survival by the Kaplan-Meier method was 48% after 36 months with a plateau at 36 months after transplantation. Intensive consolidation with high-dose arabinoside resulted in an improved survival (p-value = 0.0001), as did grade II acute graft-versus-host disease (p-value = 0.0377) and mild chronic graft-versus-host disease (p-value < 0.0001). Thirteen patients died, five due to infection within 100 days of transplant, two due to hemorrhages, one to infection and graftversus-host disease and three relapses followed by renal failure (one) and infection (two). The cause of death could not be determined for two patients.ConclusionThe busulfan and melphalan conditioning regimen is as good as other conditioning regimens providing an excellent survival rate.

show abstract

Section: Discussionmentioning

confidence: 99%